N-Acetyl Selank Amidate
N-Acetyl-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (N-acetylated, C-terminal amidated analog of Selank/TP-7)
Investigational derivative of selank. Not FDA-approved or evaluated for compounding. Available as a research chemical.
A chemically stabilized version of Selank, an anti-anxiety peptide developed in Russia, modified to last longer in the body. No human trials exist for this specific form; its expected effects on anxiety and thinking ability are based on studies of the original Selank compound.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Safety data is primarily extrapolated from the parent compound Selank, not from direct NA-Selank-Amidate studies. Published Selank clinical trials (sample sizes ~60-70 patients, durations up to ~1 month) reported no treatment-related serious adverse events and no dose-limiting toxicities (PMID: 25176261, PMID: 26356395). No FAERS or EudraVigilance safety signals found for NA-Selank-Amidate as of March 2026. No chronic toxicology, carcinogenicity, reproductive toxicology, or organ-impairment studies have been published. Preclinical rodent data for Selank show no tolerance, tachyphylaxis, withdrawal effects, or dependence signals (PMC5322660; PMID: 24913576). The absence of long-term safety data should NOT be interpreted as evidence of absence of risk.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-11]